Clinical Trials Logo

Clinical Trial Summary

Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01095120
Study type Interventional
Source Genta Incorporated
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 2010
Completion date October 2012

See also
  Status Clinical Trial Phase
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT04077255 - EGFR-targeted Therapy for Gastric Cancer Phase 2
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT00098527 - FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Terminated NCT00871273 - Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Phase 4
Recruiting NCT05729646 - Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Phase 1
Recruiting NCT05315830 - A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric Phase 1
Completed NCT00062374 - Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction Phase 2
Not yet recruiting NCT05970627 - Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Active, not recruiting NCT02202759 - A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction Phase 2
Recruiting NCT01962519 - Early Oral Feeding After Total Gastrectomy for Cancer N/A
Completed NCT00607594 - Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06121700 - Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Phase 2
Terminated NCT03722108 - Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Phase 1/Phase 2
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT02678182 - Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Phase 2
Completed NCT01640782 - Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Phase 3
Recruiting NCT05872685 - Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) Phase 2